Humacyte HUMA 深 滬
等待開盤 08-21 09:30:00 美东时间
0.6852
-0.050
-6.76%
華盛通- 最 高0.715
- 今 開0.706
- 成交量 526.79万股
- 最 低 0.6627
- 昨 收 0.7349
- 總市值 1.90亿
- 52周最高 2.55
- 市盈率 靜 --
- 換手率 1.90%
- 52周最低 0.5261
- 委 比 84.23%
- 總股本 2.78亿
- 歷史最高 17.45
- 量 比 0.27
- 振 幅 7.12%
- 歷史最低 0.5261
- 每 手 1
- 風險率 0.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | Moderna狂飙177%！美银火速将其目标价翻两番；油气股SOC升近20%
Moderna狂飙177%！美银火速将其目标价翻两番，TEM、BNTX受利好分别升24%、22%；；油气股SOC升近20%，法院裁定其加州管道重启工作将继续进行>>
08-20 16:20
Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”
Humacyte's Symvess, the first FDA-approved bioengineered human blood vessel, is now being used in Arizona by Dr. Jeromy Brink, a vascular surgeon at Banner University Medical Center in Phoenix. Symvess is an off-the-shelf solution for urgent revascularization in adults with extremity arterial injury, eliminating the need to harvest veins from patients. Dr. Brink, who has performed four implants since gaining access two weeks ago, calls Symvess th...
08-18 12:00
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
Benchmark Maintains Speculative Buy on Humacyte, Lowers Price Target to $1
Benchmark analyst Bruce D. Jackson maintains Humacyte (NASDAQ:HUMA) with a Speculative Buy and lowers the price target from $2 to $1.
08-13 21:26
Humacyte Q2 EPS $(0.16) Misses $(0.10) Estimate, Sales $406.000K Miss $1.116M Estimate
Humacyte (NASDAQ:HUMA) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.10) by 60 percent. This is a 33.33 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $406.000 thousand whic...
08-12 19:01
美股大行评级 | 潜在涨幅129.15%！HC Wainwright & Co.升Q32 Bio(QTTB)目标价至36美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Q32 Bio"买入"评级，目标价从13美元升至36美元；Chardan Capital：维持ProMIS Neurosciences"买入"评级，目标价从20美元升至33美元
07-29 11:37
BTIG Reiterates Buy on Humacyte, Maintains $2 Price Target
BTIG analyst Ryan Zimmerman reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $2 price target.
07-29 00:53
美股大行评级 | 花旗维持美光科技"买入"评级！目标价从840美元升至1200美元
今日重点评级关注：Chardan Capital：维持SAB Biotherapeutics"买入"评级，目标价从14美元升至16美元；Northland Capital Markets：维持Applied Digital"跑赢大市"评级，目标价从56美元升至82美元
06-18 19:08
TD Cowen Maintains Buy on Humacyte, Lowers Price Target to $1.25
TD Cowen analyst Joshua Jennings maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $1.5 to $1.25.
06-17 22:00
美股大行评级 | 甲骨文绩后分歧大！5家上调，2家下调；Navan、Hinge Health、凯西通用获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从6美元升至10美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14美元升至14.5美元
06-12 11:32
